FIELD: pharmaceuticals.
SUBSTANCE: invention discloses an enantiomeric compound, which is (-)-2-[(2-(4-fluorobenzoyl)phenyl)amine]-3-[(4-(2-carbazole-ethoxy)phenyl)]propionic acid of formula (I) or its pharmaceutical salt, and method obtaining the compound and use thereof.
EFFECT: enantiomeric compound demonstrates relatively better activation of expression RXR/PPAR-, RXR/PPAR- and RXR/PPAR-heterodimers and low sugar content in the db/db mouse model compared to the (+)-enantiomer.
11 cl, 3 dwg, 4 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| BENZYLAMINE DERIVATIVES AS INHIBITORS OF PLASMA KALLIKREIN | 2012 |
|
RU2607045C2 |
| SUBSTITUTED PYRIMIDINYLFORMYLOXIME DERIVATIVE, ITS PRODUCTION METHOD, ITS HERBICIDAL COMPOSITION, AND USE | 2018 |
|
RU2777594C2 |
| CYCLIC AMINE COMPOUNDS | 2002 |
|
RU2299207C2 |
| INDOLE COMPOUND AND USE THEREOF | 2006 |
|
RU2416601C2 |
| QUINAZOLINE DERIVATIVES INHIBITING EGFR ACTIVITY | 2009 |
|
RU2505534C2 |
| METHOD OF PRODUCING A PHENYLALANINE COMPOUND | 2017 |
|
RU2708243C1 |
| PHENYLCARBAMATES AND USE THEREOF AS ENZYME INHIBITORS OF HYDROLASES OF FATTY ACID AMIDES (FAAH) AND DOPAMINE RECEPTOR D3 (D3DR) MODULATORS | 2014 |
|
RU2693457C2 |
| SUBSTITUTED PYRIDINE AND PYRAZINE COMPOUNDS AS PDE4 INHIBITORS | 2014 |
|
RU2802185C2 |
| NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | 2005 |
|
RU2394021C2 |
| COMPOSITIONS FOR ACTIVATION OF LIPOPROTEIN LIPASE CONTAINING BENZENE DERIVATIVES | 2008 |
|
RU2466725C2 |
